244 related articles for article (PubMed ID: 21851460)
1. Predictors of fluoxetine remission for hospitalized patients with major depressive disorder.
Lin CH; Lane HY; Chen CC; Juo SH; Yen CF
Psychiatry Clin Neurosci; 2011 Aug; 65(5):510-7. PubMed ID: 21851460
[TBL] [Abstract][Full Text] [Related]
2. Pain has a strong negative impact on the fluoxetine response in hospitalized patients with major depressive disorder.
Lin CH; Lane HY; Chen CC; Juo SH; Yen CF
Clin J Pain; 2011; 27(9):805-10. PubMed ID: 21677571
[TBL] [Abstract][Full Text] [Related]
3. Does early improvement triggered by antidepressants predict response/remission? Analysis of data from a naturalistic study on a large sample of inpatients with major depression.
Henkel V; Seemüller F; Obermeier M; Adli M; Bauer M; Mundt C; Brieger P; Laux G; Bender W; Heuser I; Zeiler J; Gaebel W; Mayr A; Möller HJ; Riedel M
J Affect Disord; 2009 Jun; 115(3):439-49. PubMed ID: 19027961
[TBL] [Abstract][Full Text] [Related]
4. Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial.
Detke MJ; Wiltse CG; Mallinckrodt CH; McNamara RK; Demitrack MA; Bitter I
Eur Neuropsychopharmacol; 2004 Dec; 14(6):457-70. PubMed ID: 15589385
[TBL] [Abstract][Full Text] [Related]
5. Antidepressant response and well-being in pre-, peri- and postmenopausal women with major depressive disorder treated with fluoxetine.
Cassano P; Soares CN; Cusin C; Mascarini A; Cohen LS; Fava M
Psychother Psychosom; 2005; 74(6):362-5. PubMed ID: 16244512
[TBL] [Abstract][Full Text] [Related]
6. Difference in pre- and post-treatment plasma DHEA levels were significantly and positively correlated with difference in pre- and post-treatment Hamilton depression scores following successful therapy for major depression.
Hsiao CC
Psychoneuroendocrinology; 2006 Aug; 31(7):839-46. PubMed ID: 16716529
[TBL] [Abstract][Full Text] [Related]
7. Fluoxetine once every third day in the treatment of major depressive disorder.
Tural U; Onder E
Eur Arch Psychiatry Clin Neurosci; 2003 Dec; 253(6):307-12. PubMed ID: 14714120
[TBL] [Abstract][Full Text] [Related]
8. Hopelessness as a predictor of non-response to fluoxetine in major depressive disorder.
Papakostas GI; Petersen T; Homberger CH; Green CH; Smith J; Alpert JE; Fava M
Ann Clin Psychiatry; 2007; 19(1):5-8. PubMed ID: 17453655
[TBL] [Abstract][Full Text] [Related]
9. Comparison of mirtazapine and fluoxetine in the treatment of major depressive disorder: a double-blind, randomized trial.
Amini H; Aghayan S; Jalili SA; Akhondzadeh S; Yahyazadeh O; Pakravan-Nejad M
J Clin Pharm Ther; 2005 Apr; 30(2):133-8. PubMed ID: 15811165
[TBL] [Abstract][Full Text] [Related]
10. A randomized, double-blind, and placebo-controlled trial of quetiapine augmentation of fluoxetine in major depressive disorder.
Garakani A; Martinez JM; Marcus S; Weaver J; Rickels K; Fava M; Hirschowitz J
Int Clin Psychopharmacol; 2008 Sep; 23(5):269-75. PubMed ID: 18703936
[TBL] [Abstract][Full Text] [Related]
11. Fluoxetine versus trimipramine in the treatment of depression in geriatric patients.
Wehmeier PM; Kluge M; Maras A; Riemann D; Berger M; Kohnen R; Dittmann RW; Gattaz WF
Pharmacopsychiatry; 2005 Jan; 38(1):13-6. PubMed ID: 15706460
[TBL] [Abstract][Full Text] [Related]
12. Achieving remission with venlafaxine and fluoxetine in major depression: its relationship to anxiety symptoms.
Davidson JR; Meoni P; Haudiquet V; Cantillon M; Hackett D
Depress Anxiety; 2002; 16(1):4-13. PubMed ID: 12203668
[TBL] [Abstract][Full Text] [Related]
13. Switching to reboxetine: an efficacy and safety study in patients with major depressive disorder unresponsive to fluoxetine.
Fava M; McGrath PJ; Sheu WP;
J Clin Psychopharmacol; 2003 Aug; 23(4):365-9. PubMed ID: 12920412
[TBL] [Abstract][Full Text] [Related]
14. Residual symptoms after remission of major depressive disorder with fluoxetine and risk of relapse.
Iovieno N; van Nieuwenhuizen A; Clain A; Baer L; Nierenberg AA
Depress Anxiety; 2011 Feb; 28(2):137-44. PubMed ID: 21284066
[TBL] [Abstract][Full Text] [Related]
15. Psychic and somatic anxiety symptoms as predictors of response to fluoxetine in major depressive disorder.
Papakostas GI; McGrath P; Stewart J; Charles D; Chen Y; Mischoulon D; Dording C; Fava M
Psychiatry Res; 2008 Oct; 161(1):116-20. PubMed ID: 18755514
[TBL] [Abstract][Full Text] [Related]
16. Relief of depression and pain improves daily functioning and quality of life in patients with major depressive disorder.
Lin CH; Yen YC; Chen MC; Chen CC
Prog Neuropsychopharmacol Biol Psychiatry; 2013 Dec; 47():93-8. PubMed ID: 23989033
[TBL] [Abstract][Full Text] [Related]
17. Major depressive subtypes and treatment response.
Fava M; Uebelacker LA; Alpert JE; Nierenberg AA; Pava JA; Rosenbaum JF
Biol Psychiatry; 1997 Oct; 42(7):568-76. PubMed ID: 9376453
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and tolerability of escitalopram versus citalopram in major depressive disorder: a 6-week, multicenter, prospective, randomized, double-blind, active-controlled study in adult outpatients.
Yevtushenko VY; Belous AI; Yevtushenko YG; Gusinin SE; Buzik OJ; Agibalova TV
Clin Ther; 2007 Nov; 29(11):2319-32. PubMed ID: 18158074
[TBL] [Abstract][Full Text] [Related]
19. Early response and remission as predictors of a good outcome of a major depressive episode at 12-month follow-up: a prospective, longitudinal, observational study.
Ciudad A; Álvarez E; Roca M; Baca E; Caballero L; García de Polavieja P; Casillas M; Valladares A; Gilaberte I
J Clin Psychiatry; 2012 Feb; 73(2):185-91. PubMed ID: 22053897
[TBL] [Abstract][Full Text] [Related]
20. Why do some depressed outpatients who are in remission according to the Hamilton Depression Rating Scale not consider themselves to be in remission?
Zimmerman M; Martinez JA; Attiullah N; Friedman M; Toba C; Boerescu DA; Rahgeb M
J Clin Psychiatry; 2012 Jun; 73(6):790-5. PubMed ID: 22569085
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
